Petros Pharmaceuticals, Inc. (PTPI) Return on equity 2020–2023
Petros Pharmaceuticals, Inc. (PTPI) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-67.6%FY2023 · since FY2020: -117.8% → -67.6%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2023 | -67.6% | +52.3 pp |
| FY2022 | -120.0% | -94.7 pp |
| FY2021 | -25.3% | +92.6 pp |
| FY2020 | -117.8% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice
More PTPI financial trends
PTPI RevenuePTPI Net incomePTPI Net marginPTPI Gross profitPTPI Gross marginPTPI Operating incomePTPI Operating marginPTPI Operating cash flowPTPI Free cash flowPTPI Capital expendituresPTPI Stock buybacksPTPI Dividends paidPTPI Total assetsPTPI Total liabilitiesPTPI Shareholders’ equityPTPI overview →